These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 10991664)
1. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. Chase TN; Oh JD; Konitsiotis S J Neurol; 2000 Apr; 247 Suppl 2():II36-42. PubMed ID: 10991664 [TBL] [Abstract][Full Text] [Related]
2. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications. Chase TN; Oh JD Ann Neurol; 2000 Apr; 47(4 Suppl 1):S122-9; discussion S129-30. PubMed ID: 10762139 [TBL] [Abstract][Full Text] [Related]
3. Non-NMDA receptor-mediated mechanisms are involved in levodopa-induced motor response alterations in Parkinsonian rats. Marin C; Jimenez A; Bonastre M; Chase TN; Tolosa E Synapse; 2000 Jun; 36(4):267-74. PubMed ID: 10819904 [TBL] [Abstract][Full Text] [Related]
4. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Bibbiani F; Oh JD; Kielaite A; Collins MA; Smith C; Chase TN Exp Neurol; 2005 Dec; 196(2):422-9. PubMed ID: 16203001 [TBL] [Abstract][Full Text] [Related]
5. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits. Oh JD; Vaughan CL; Chase TN Brain Res; 1999 Mar; 821(2):433-42. PubMed ID: 10064831 [TBL] [Abstract][Full Text] [Related]
6. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Chase TN Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164 [TBL] [Abstract][Full Text] [Related]
7. Gene transfer of constitutively active protein kinase C into striatal neurons accelerates onset of levodopa-induced motor response alterations in parkinsonian rats. Oh JD; Geller AI; Zhang Gr; Chase TN Brain Res; 2003 May; 971(1):18-30. PubMed ID: 12691833 [TBL] [Abstract][Full Text] [Related]
15. Glutamate receptors as therapeutic targets for Parkinson's disease. Johnson KA; Conn PJ; Niswender CM CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565 [TBL] [Abstract][Full Text] [Related]
16. Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Oh JD; Chase TN Amino Acids; 2002; 23(1-3):133-9. PubMed ID: 12373527 [TBL] [Abstract][Full Text] [Related]
17. New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors. Blandini F; Armentero MT Expert Opin Investig Drugs; 2012 Feb; 21(2):153-68. PubMed ID: 22233485 [TBL] [Abstract][Full Text] [Related]
18. Novel pharmacological strategies for motor complications in Parkinson's disease. Konitsiotis S Expert Opin Investig Drugs; 2005 Apr; 14(4):377-92. PubMed ID: 15882115 [TBL] [Abstract][Full Text] [Related]
19. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Chase TN Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518 [TBL] [Abstract][Full Text] [Related]
20. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Verhagen Metman L; Del Dotto P; Blanchet PJ; van den Munckhof P; Chase TN Amino Acids; 1998; 14(1-3):75-82. PubMed ID: 9871445 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]